Holen Sie sich die Stockscreener-App
35.44
0.84%
-0.30
Vorhandelsmarkt:
36.20
0.76
+2.14%
Schlusskurs vom Vortag:
$35.74
Offen:
$35.86
24-Stunden-Volumen:
583.59K
Relative Volume:
0.52
Marktkapitalisierung:
$4.14B
Einnahmen:
$22.57M
Nettoeinkommen (Verlust:
$-212.73M
KGV:
-19.64
EPS:
-1.8045
Netto-Cashflow:
$-142.19M
1W Leistung:
+0.00%
1M Leistung:
+10.96%
6M Leistung:
-7.39%
1J Leistung:
+93.87%
1-Tages-Spanne:
$35.01
$36.73
1-Wochen-Bereich:
$32.96
$36.73
52-Wochen-Spanne:
$16.79
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
35.44 | 4.18B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Technical Reactions to NAMS Trends in Macro Strategies - Stock Traders Daily
NewAmsterdam Pharma Co NV (HAM:KH6) Cyclically Adjusted Pri - GuruFocus
Bain Life Sciences trims NewAmsterdam (NAMS) holding to about 3.3% - Stock Titan
Trading the Move, Not the Narrative: (NAMS) Edition - Stock Traders Daily
NewAmsterdam Pharma Company N.V.Ordinary Shares (NQ: NAMS - FinancialContent
Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts - Sahm
NewAmsterdam Pharma Company N.V. (NAMS) Eps Diluted (TTM) - Zacks Investment Research
NAMS: Interim PREVAIL results expected Q1 next year, with strong efficacy and broad market potential - TradingView
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight By Investing.com - Investing.com Nigeria
Piper Sandler reiterates NewAmsterdam Pharma stock rating at overweight - Investing.com
HC Wainwright Has Negative Forecast for NAMS Q2 Earnings - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 42.02 USD By Investing.com - Investing.com India
TradingKey - TradingKey
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL TrialSlideshow (NASDAQ:NAMS) 2026-05-11 - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones - simplywall.st
NewAmsterdam Pharma stock hits all-time high at 42.02 USD - Investing.com
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May - GlobeNewswire
Number of shareholders of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NewAmsterdam Pharma Company NV (NAMS) reports Q1 loss, tops revenue estimates - MSN
NewAmsterdam Pharma Hits Day High with 12.46% Surge in Stock Price - Markets Mojo
NewAmsterdam Pharma (NAMS) Deep Quarterly Loss Tests Bullish Growth And Valuation Narratives - Sahm
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam says its 9,500-patient heart trial gets an interim look in 4Q26 - Stock Titan
Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses? - Yahoo Finance
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends - Yahoo Finance
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom - ChartMill
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q1 Revenue $3.0M, vs. FactSet Est of $1.1M - marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q1 Revenue $3.0M, Vs. FactSet Est of $1.1M - Moomoo
NewAmsterdam Pharma (NAMS) posts Q1 2026 loss with $707M cash and key trial milestones - Stock Titan
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - marketscreener.com
NewAmsterdam Pharma (NASDAQ: NAMS) reports $48M Q1 2026 loss - Stock Titan
Number of shareholders of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
All eyes on NewAmsterdam Pharma earnings as pipeline advances By Investing.com - Investing.com Nigeria
All eyes on NewAmsterdam Pharma earnings as pipeline advances - Investing.com
FMR LLC boosts disclosure: PHARMA COMPANY NV (NAMS) 8.77M shares reported - Stock Titan
[ARS] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma (NAMS) outlines 2026 AGM votes, ESPP and share issuance powers - Stock Titan
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Five new hires at NewAmsterdam get stock awards covering 65,800 shares - Stock Titan
Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Jennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
What sustainable investing NewAmsterdam (NAMSW)? (+5.61%) 2026-04-29Community Watchlist - Newser
143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLC - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8%What's Next? - MarketBeat
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):